---
title: "Obefazimod (ABX464) in Ulcerative colitis: Indication"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Indication. Topics: Proposed indication: adults with moderately to severely active ulcerative colitis; Population of the pivotal ABTECT trials: inadequate response to conventional or advanced therapy; Indication targeted by the EU paediatric investigation plan; Crohn's disease in development: phase 2b ENHANCE-CD, induction topline results expected mid-2027; 1 further topic. 5 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/indication"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Indication

<a id="heading-2.1.2.5"></a>

## 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

### Proposed indication: adults with moderately to severely active ulcerative colitis

> “today announced the successful completion of its positive pre-New Drug Application (NDA) interaction with the U.S. Food and Drug Administration (FDA) for obefazimod for the treatment of adults with moderately to severely active ulcerative colitis (UC).”
> “Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026”

Source: [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod)

<a id="topic-2.1.2.5-2"></a>

### Population of the pivotal ABTECT trials: inadequate response to conventional or advanced therapy

> “The ABTECT-1 and ABTECT-2 induction trials are global, multicenter, randomized, double-blind, placebo-controlled trials assessing once-daily oral administration of obefazimod at 25 mg or 50 mg doses in adult patients with moderately to severely active UC. Eligible participants had inadequate response, loss of response, or intolerance to conventional and/or advanced therapies.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

> “Subjects with documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids, immunosuppressant, biologic or biosimilar therapies, S1P receptor modulators and/or JAK inhibitors and/or new drugs approved during the study (note: failure to only 5-ASA or sulfasalazine is not accepted).”
> “Men or women at least 16 years old; Adolescent subjects will only be enrolled if approved by the country regulatory/health authority.”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-2.1.2.5-3"></a>

### Indication targeted by the EU paediatric investigation plan

> “Treatment of patients diagnosed with moderately to severely active ulcerative colitis (UC)”
> “From 2 years to less than 18 years of age”

Source: [EMA paediatric investigation plan decision, March 2025 (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000189672-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod_en.pdf)

<a id="topic-2.1.2.5-4"></a>

### Crohn's disease in development: phase 2b ENHANCE-CD, induction topline results expected mid-2027

> “Mid-2027 – Topline results from the Phase 2b ENHANCE-CD induction trial evaluating obefazimod in CD”

Source: [Abivax first half 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-business-updates-and-first-half-2026-financial)

> “Patient enrollment for ENHANCE-CD in Crohn’s disease was initiated in Q3 2024; 12-week induction data readout is anticipated mid-year 2027.”

Source: [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/)

> “This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase.”
> “Obefazimod 12.5mg given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)”

Source: [ClinicalTrials.gov NCT06456593](https://clinicaltrials.gov/study/NCT06456593)

<a id="topic-2.1.2.5-5"></a>

### ENHANCE-CD induction results timing, January to May 2026, superseded in June 2026

> “Topline results of Phase 2b induction trial for CD - Q4 2026”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

> “Completion of Phase 2b induction trial for CD - Q4 2026”

Source: [Abivax full year 2025 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-full-year-2025-financial-results-and-provides)

> “The 12-week induction trial results are anticipated in late 2026 and will help inform the design of subsequent registrational studies.”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

Additional sources: [Honap et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42322247/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
